Related Experiment Video
Updated: Dec 29, 2025
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Anlotinib is effective in patients with advanced oral cancer?
Chen Chu1, Wei Shang2, Yan Sun3
1Department of Stomatology, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong, China; School of Stomatology of Qingdao University, Qingdao 266000, Shandong, China; Department of Oral and Maxillofacial Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266000, Shandong, China.
Abstract:
Oral cancer patients with recurrence or distant metastasis often present poor prognosis. Majority of advanced oral cancer patients suffer from treat-related adverse events and drug resistance. For those patients, the survival time and quality of life are urgent to be improved. Anlotinib, as a multi-targets tyrosine kinase inhibitor (TKI), has been demonstrated to be effective in many refractory tumors by inhibiting tumor angiogenesis and partial functions of tumor cells. In this paper, we performed CCK-8 assay, wound healing assay and transwell assay to explore the effect of anlotinib on human tongue squamous carcinoma Tca8113 cell line. Preliminary data indicated that anlotinib significantly inhibited Tca8113 cells proliferation, migration and invasion in vitro. Together, we proposed a hypothesis that anlotinib might be effective in prolonging survival time of patients with advanced oral cancer.
Insights
Anlotinib, a tyrosine kinase inhibitor (TKI), shows promise for advanced oral cancer. This drug significantly inhibited oral cancer cell proliferation, migration, and invasion in laboratory studies.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced oral cancer, particularly with recurrence or metastasis, has a poor prognosis.
- Patients often face treatment-related adverse events and drug resistance, necessitating improved survival and quality of life.
- Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) with demonstrated efficacy in refractory tumors by inhibiting angiogenesis and tumor cell functions.
Purpose of the Study:
- To investigate the effects of anlotinib on the human tongue squamous carcinoma Tca8113 cell line.
- To evaluate anlotinib's potential as a therapeutic agent for advanced oral cancer.
Main Methods:
- Cell Counting Kit-8 (CCK-8) assay was used to assess cell proliferation.
- Wound healing assay was employed to evaluate cell migration.
- Transwell assay was utilized to determine cell invasion.
Main Results:
- Anlotinib significantly inhibited the proliferation of Tca8113 cells in vitro.
- Anlotinib demonstrated significant inhibition of Tca8113 cell migration.
- Anlotinib also significantly reduced the invasion capabilities of Tca8113 cells in vitro.
Conclusions:
- Anlotinib exhibits potent anti-cancer effects on human tongue squamous carcinoma cells in vitro.
- These findings support the hypothesis that anlotinib may be effective in prolonging survival for patients with advanced oral cancer.
More Related Videos
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
